Alpine and Merck Study Checkpoint, Anti-PD-1 Cancer Combo in Collab Study

Clinical-stage immunotherapy company Alpine Immune Sciences has entered into a collaboration agreement with Merck to evaluate the efficacy and safety of Alpine’s checkpoint in combination with Merk’s anti-PD-1 therapy in cancer.